Should I buy or sell COMPASS Pathways stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CMPS shares. View CMPS analyst ratings or view top-rated stocks .

What is COMPASS Pathways' stock price target for 2024?

5 brokers have issued 1-year price targets for COMPASS Pathways' shares. Their CMPS share price targets range from $16.00 to $120.00. On average, they anticipate the company's share price to reach $47.40 in the next twelve months. This suggests a possible upside of 456.3% from the stock's current price. View analysts price targets for CMPS or view top-rated stocks among Wall Street analysts .

How have CMPS shares performed in 2024?

COMPASS Pathways' stock was trading at $8.75 at the beginning of the year. Since then, CMPS stock has decreased by 2.6% and is now trading at $8.52. View the best growth stocks for 2024 here .

When is COMPASS Pathways' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CMPS earnings forecast .

How were COMPASS Pathways' earnings last quarter?

COMPASS Pathways plc (NASDAQ:CMPS) announced its quarterly earnings data on Thursday, February, 29th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.16.

What ETFs hold COMPASS Pathways' stock?

ETFs with the largest weight of COMPASS Pathways (NASDAQ:CMPS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL) , Subversive Mental Health ETF (SANE) and ARK Genomic Revolution ETF (ARKG) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

What other stocks do shareholders of COMPASS Pathways own?

Based on aggregate information from My MarketBeat watchlists, some companies that other COMPASS Pathways investors own include Nikola (NKLA) , Vaxart (VXRT) , Beyond Meat (BYND) , Evofem Biosciences (EVFM) , GrowGeneration (GRWG) , McDonald's (MCD) , Plug Power (PLUG) , Block (SQ) , Workhorse Group (WKHS) and

When did COMPASS Pathways IPO?

COMPASS Pathways (CMPS) raised $100 million in an initial public offering on Friday, September 18th 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

How do I buy shares of COMPASS Pathways?

Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CMPS

COMPASS Pathways (CMPS) Stock Price, News & Analysis

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

Free CMPS Stock Alerts

$8.50

-0.03 (-0.35%)

(As of 01:03 PM ET)

Compare

Today's Range: $8.31
▼
$8.69
50-Day Range: $8.32
▼
$12.37
52-Week Range: $5.01
▼
$12.75

Volume: 95,858 shs
Average Volume: 691,559 shs
Market Capitalization: $526.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $47.40

Get COMPASS Pathways alerts:

COMPASS Pathways MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 456.3% Upside
$47.40 Price Target
Short Interest: Bearish
5.05% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.30
Based on 4 Articles This Week
Insider Trading: Selling Shares
$1.51 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.40) to ($2.52) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.04 out of 5 stars

Medical Sector

605th out of 914 stocks

Pharmaceutical Preparations Industry

276th out of 418 stocks

3.5

Analyst's Opinion

Consensus Rating
COMPASS Pathways has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
COMPASS Pathways has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.05% of the outstanding shares of COMPASS Pathways have been sold short.
Short Interest Ratio / Days to Cover
COMPASS Pathways has a short interest ratio ("days to cover") of 4.3.
Change versus previous month
Short interest in COMPASS Pathways has recently decreased by 0.63%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
COMPASS Pathways does not currently pay a dividend.
Dividend Growth
COMPASS Pathways does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CMPS.

2.4

News and Social Media Coverage

News Sentiment
COMPASS Pathways has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for COMPASS Pathways this week, compared to 2 articles on an average week.
Search Interest
Only 15 people have searched for CMPS on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.
MarketBeat Follows
23 people have added COMPASS Pathways to their MarketBeat watchlist in the last 30 days. This is an increase of 28% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, COMPASS Pathways insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,511,656.00 in company stock.
Percentage Held by Insiders
23.99% of the stock of COMPASS Pathways is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
46.19% of the stock of COMPASS Pathways is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for COMPASS Pathways are expected to decrease in the coming year, from ($2.40) to ($2.52) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of COMPASS Pathways is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of COMPASS Pathways is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
COMPASS Pathways has a P/B Ratio of 2.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto Swap Profits

Claim Your Complimentary Bitcoin Reward

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

Secure Your Spot Now

About COMPASS Pathways Stock (NASDAQ:CMPS)

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

CMPS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CMPS Stock News Headlines

April 3, 2024 | insidertrades.com

Insider Selling: COMPASS Pathways plc (NASDAQ:CMPS) Major Shareholder Sells 25,750 Shares of Stock

April 13, 2024 | americanbankingnews.com

Head to Head Contrast: COMPASS Pathways (NASDAQ:CMPS) & Evelo Biosciences (NASDAQ:EVLO)

April 18, 2024 | Priority Gold (Ad)

Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

April 4, 2024 | investing.com

Compass Pathways insider sells over $460k in shares

April 1, 2024 | globenewswire.com

Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference

April 1, 2024 | markets.businessinsider.com

Buy Rating on COMPASS Pathways: COMP360’s Market Potential and Promising TRD Therapy

March 31, 2024 | finance.yahoo.com

20 Most Depressed Countries in Asia

March 30, 2024 | uk.investing.com

Compass Pathways co-founders step down from board

April 18, 2024 | Priority Gold (Ad)

Biden to Launch “FedNOW” [Move Your Money Now]

March 28, 2024 | globenewswire.com

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

March 19, 2024 | markets.businessinsider.com

Buy Rating Affirmed for COMPASS Pathways Amid Promising Neuropsychiatric Treatment Advances

March 16, 2024 | investing.com

Compass Pathways director sells over $700k in company shares

March 5, 2024 | fool.com

3 Biopharma Stocks You Don't Want to Miss in the New Bull Market

March 1, 2024 | finance.yahoo.com

COMPASS Pathways plc (NASDAQ:CMPS) Q4 2023 Earnings Call Transcript

February 29, 2024 | marketwatch.com

Compass Pathways Shares Tumble 18% After Warning of Trial Delay

February 29, 2024 | finance.yahoo.com

Compass Pathways PLC Reports Increased Annual Net Loss Amid Clinical Advancements

February 29, 2024 | globenewswire.com

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights

February 27, 2024 | investorplace.com

Penny Power Players: 3 Stocks to Watch in the Microcap Arena

February 26, 2024 | globenewswire.com

Compass Pathways to participate in upcoming TD Cowen investor conference

February 22, 2024 | finance.yahoo.com

Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024

February 22, 2024 | globenewswire.com

Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024

February 21, 2024 | investorplace.com

Mental Health Mavericks: 3 Stocks Changing the Game

February 19, 2024 | fool.com

Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.

February 19, 2024 | fool.com

Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.

February 17, 2024 | finance.yahoo.com

CMPS Mar 2024 10.000 call

February 13, 2024 | finance.yahoo.com

COMPASS Pathways plc (CMPS)

February 8, 2024 | seekingalpha.com

Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play

See More Headlines

Receive CMPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CMPS
CUSIP: N/A
CIK: 1816590
Web: www.compasspathways.com
Phone: 716-676-6461
Fax: N/A
Employees: 186
Year Founded: 2016

Price Target and Rating

Average Stock Price Target: $47.40
High Stock Price Target: $120.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +451.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-118,460,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -58.72%
Return on Assets: -49.46%

Debt

Debt-to-Equity Ratio: 0.14
Current Ratio: 13.33
Quick Ratio: 13.33

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.65 per share
Price / Book: 2.36

Miscellaneous

Outstanding Shares: 61,940,000
Free Float: 47,083,000
Market Cap: $532.68 million
Optionable: Optionable
Beta: 2.48

Social Links

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Kabir Nath M.A. (Age 60)
M.B.A., CEO & Director
Comp: $1.31M
Mr. Matthew Allen Owens (Age 47)
General Counsel & Chief Legal Officer
Comp: $684.51k
Dr. Guy Goodwin (Age 76)
Chief Medical Officer
Comp: $567k
Ms. Teri Loxam M.B.A. (Age 51)
CFO, Principal Financial Officer & Principal Accounting Officer
Dr. Greg Ryslik Ph.D.
Chief Technology Officer
Mr. Stephen D. Schultz
Senior Vice President of Investor Relations
Mr. Christopher Williams
Chief Communications Officer
Ms. Anne Benedict
Chief People Officer
Mr. Lars Christian Wilde (Age 39)
Senior Advisor
Mr. Trevor Mill
Chief Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CMPS Stock Analysis - Frequently Asked Questions

Should I buy or sell COMPASS Pathways stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CMPS shares.
View CMPS analyst ratings or view top-rated stocks.
What is COMPASS Pathways' stock price target for 2024?: 5 brokers have issued 1-year price targets for COMPASS Pathways' shares. Their CMPS share price targets range from $16.00 to $120.00. On average, they anticipate the company's share price to reach $47.40 in the next twelve months. This suggests a possible upside of 456.3% from the stock's current price.
View analysts price targets for CMPS or view top-rated stocks among Wall Street analysts.
How have CMPS shares performed in 2024?: COMPASS Pathways' stock was trading at $8.75 at the beginning of the year. Since then, CMPS stock has decreased by 2.6% and is now trading at $8.52.
View the best growth stocks for 2024 here.
When is COMPASS Pathways' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CMPS earnings forecast.
How were COMPASS Pathways' earnings last quarter?: COMPASS Pathways plc (NASDAQ:CMPS) announced its quarterly earnings data on Thursday, February, 29th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.16.

What ETFs hold COMPASS Pathways' stock?: ETFs with the largest weight of COMPASS Pathways (NASDAQ:CMPS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Subversive Mental Health ETF (SANE) and ARK Genomic Revolution ETF (ARKG).Virtus LifeSci Biotech Clinical Trials ETF (BBC).
What other stocks do shareholders of COMPASS Pathways own?: Based on aggregate information from My MarketBeat watchlists, some companies that other COMPASS Pathways investors own include Nikola (NKLA), Vaxart (VXRT), Beyond Meat (BYND), Evofem Biosciences (EVFM), GrowGeneration (GRWG), McDonald's (MCD), Plug Power (PLUG), Block (SQ), Workhorse Group (WKHS) and
When did COMPASS Pathways IPO?: COMPASS Pathways (CMPS) raised $100 million in an initial public offering on Friday, September 18th 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager.
How do I buy shares of COMPASS Pathways?: Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CMPS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial